-
Press ReleaseNovartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
-
Press ReleaseNovartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
-
Press ReleaseNovartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
-
Press ReleaseNew Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
-
Press ReleaseNovartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
-
Story
My journey to Novartis: Finding my purpose and passion -
Press ReleaseNovartis erzielt im ersten Quartal ein zweistelliges Umsatzwachstum und steigert die Kerngewinnmarge; Prognose für das Geschäftsjahr 2024 erhöht
-
Press ReleaseNovartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
-
Press ReleaseNovartis, au premier trimestre: croissance à deux chiffres du chiffre d’affaires et expansion de la marge core; hausse des prévisions pour 2024
-
Press ReleaseNew Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
-
Story
Drug delivery, service delivery, and the future of cancer care -
Press ReleaseNew Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting